Role of microbiota and microbiota-derived short-chain fatty acids in PDAC

Hulya  Yilmaz Temel; Oznur Kaymak; Seren  Kaplan; Basak Bahcivanci; Georgios Gkoutos; Animesh Acharjee

doi:10.1002/cam4.5323

Role of microbiota and microbiota-derived short-chain fatty acids in PDAC

Hulya Yilmaz Temel , Oznur Kaymak, Seren Kaplan, Basak Bahcivanci , Georgios Gkoutos, Animesh Acharjee^*

^*Corresponding author for this work

Cancer and Genomic Sciences

Research output: Contribution to journal › Review article › peer-review

110 Downloads (Pure)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive lethal diseases among other cancer types. Gut microbiome and its metabolic regulation play a crucial role in PDAC. Metabolic regulation in the gut is a complex process that involves microbiome and microbiome-derived short-chain fatty acids (SCFAs). SCFAs regulate inflammation, as well as lipid and glucose metabolism, through different pathways. This review aims to summarize recent developments in PDAC in the context of gut and oral microbiota and their associations with short-chain fatty acid (SCFA). In addition to this, we discuss possible therapeutic applications using microbiota in PDAC.

Original language	English
Journal	Cancer Medicine
Early online date	7 Oct 2022
DOIs	https://doi.org/10.1002/cam4.5323
Publication status	E-pub ahead of print - 7 Oct 2022

Bibliographical note

Funding Information:
This work was funded by MRC Health Data Research UK (HDRUK/CFC/01), an initiative funded by UK Research and Innovation, Department of Health and Social Care (England) and the devolved administrations, and leading medical research charities. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, the Medical Research Council or the Department of Health. Animesh Acharjee and Georgios V. Gkoutos also acknowledge support from the NIHR Birmingham SRMRC, Nanocommons H2020‐EU (731032) and MAESTRIA (Grant agreement ID 965286).

Publisher Copyright:
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Keywords

SCFA
host–microbe interactions
inflammation
microbiome
microbiota
pancreatic ductal adenocarcinoma

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.1002/cam4.5323Licence: Creative Commons: Attribution (CC BY)

2022_10_A_Cancer_MedicineFinal published version, 528 KBLicence: Creative Commons: Attribution (CC BY)

H2020_RIA_NANOCOMMONS_CO-ORDINATOR
Valsami-Jones, E., Lynch, I. & Gkoutos, G.
European Commission
1/01/18 → 30/06/22
Project: EU

Cite this

@article{d2553c01e0e54557ae0613bb476e8e41,

title = "Role of microbiota and microbiota-derived short-chain fatty acids in PDAC",

abstract = "Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive lethal diseases among other cancer types. Gut microbiome and its metabolic regulation play a crucial role in PDAC. Metabolic regulation in the gut is a complex process that involves microbiome and microbiome-derived short-chain fatty acids (SCFAs). SCFAs regulate inflammation, as well as lipid and glucose metabolism, through different pathways. This review aims to summarize recent developments in PDAC in the context of gut and oral microbiota and their associations with short-chain fatty acid (SCFA). In addition to this, we discuss possible therapeutic applications using microbiota in PDAC.",

keywords = "SCFA, host–microbe interactions, inflammation, microbiome, microbiota, pancreatic ductal adenocarcinoma",

author = "{Yilmaz Temel}, Hulya and Oznur Kaymak and Seren Kaplan and Basak Bahcivanci and Georgios Gkoutos and Animesh Acharjee",

note = "Funding Information: This work was funded by MRC Health Data Research UK (HDRUK/CFC/01), an initiative funded by UK Research and Innovation, Department of Health and Social Care (England) and the devolved administrations, and leading medical research charities. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, the Medical Research Council or the Department of Health. Animesh Acharjee and Georgios V. Gkoutos also acknowledge support from the NIHR Birmingham SRMRC, Nanocommons H2020‐EU (731032) and MAESTRIA (Grant agreement ID 965286). Publisher Copyright: {\textcopyright} 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",

year = "2022",

month = oct,

day = "7",

doi = "10.1002/cam4.5323",

language = "English",

journal = "Cancer Medicine",

issn = "2045-7634",

publisher = "John Wiley & Sons",

}

TY - JOUR

T1 - Role of microbiota and microbiota-derived short-chain fatty acids in PDAC

AU - Yilmaz Temel , Hulya

AU - Kaymak, Oznur

AU - Kaplan, Seren

AU - Bahcivanci , Basak

AU - Gkoutos, Georgios

AU - Acharjee, Animesh

N1 - Funding Information: This work was funded by MRC Health Data Research UK (HDRUK/CFC/01), an initiative funded by UK Research and Innovation, Department of Health and Social Care (England) and the devolved administrations, and leading medical research charities. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, the Medical Research Council or the Department of Health. Animesh Acharjee and Georgios V. Gkoutos also acknowledge support from the NIHR Birmingham SRMRC, Nanocommons H2020‐EU (731032) and MAESTRIA (Grant agreement ID 965286). Publisher Copyright: © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

PY - 2022/10/7

Y1 - 2022/10/7

N2 - Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive lethal diseases among other cancer types. Gut microbiome and its metabolic regulation play a crucial role in PDAC. Metabolic regulation in the gut is a complex process that involves microbiome and microbiome-derived short-chain fatty acids (SCFAs). SCFAs regulate inflammation, as well as lipid and glucose metabolism, through different pathways. This review aims to summarize recent developments in PDAC in the context of gut and oral microbiota and their associations with short-chain fatty acid (SCFA). In addition to this, we discuss possible therapeutic applications using microbiota in PDAC.

AB - Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive lethal diseases among other cancer types. Gut microbiome and its metabolic regulation play a crucial role in PDAC. Metabolic regulation in the gut is a complex process that involves microbiome and microbiome-derived short-chain fatty acids (SCFAs). SCFAs regulate inflammation, as well as lipid and glucose metabolism, through different pathways. This review aims to summarize recent developments in PDAC in the context of gut and oral microbiota and their associations with short-chain fatty acid (SCFA). In addition to this, we discuss possible therapeutic applications using microbiota in PDAC.

KW - SCFA

KW - host–microbe interactions

KW - inflammation

KW - microbiome

KW - microbiota

KW - pancreatic ductal adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=85139447249&partnerID=8YFLogxK

U2 - 10.1002/cam4.5323

DO - 10.1002/cam4.5323

M3 - Review article

C2 - 36205023

SN - 2045-7634

JO - Cancer Medicine

JF - Cancer Medicine

ER -

Role of microbiota and microbiota-derived short-chain fatty acids in PDAC

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Projects

H2020_RIA_NANOCOMMONS_CO-ORDINATOR

Cite this